

# Pressure BioSciences, Inc.

10:20 28 May 2020

## Pressure BioSciences merger partner Cannaworx to launch hemp immune boosting product in mid-July

Pressure BioSciences Inc (OTCQB:PBIO) announced Thursday that its pending merger partner Cannaworx Inc will launch a patented proprietary hemp immune booster supplement by mid-July.

Once it hits the market, the company believes this product could be one of very few over-the-counter, FDA-registered hemp supplements products — if not the only one — that can claim to be an immune booster.

The active ingredient in the Cannaworx immune booster is a patented, proprietary blend of 44 amino acid fragments from pepsin, the company said. The product, enhanced with hemp seed oil, increases the number of helper T cells in the body, which boosts immune response by enabling macrophage cells to kill and consume bacteria, viruses and other invaders.

### READ: Pressure BioSciences says Cannaworx in potential deal to acquire Five Leaf Labs in Louisiana

"To further enhance the immune boosting effect, we added hemp seed oil (no THC) to our patented formulation," Cannaworx President Bobby Ghalili said in a statement. "Hemp seed oil is rich in essential fatty acids (like omega-6 and omega-3) and antioxidants that may help fight inflammation, cancer, diabetes, and heart disease.

"Omega-3 is also thought to have a positive impact on the bowel microbiome as a prebiotic, providing further support to the immune system. The manufacturing process of the patented 44 amino acid fragment formulation is highly proprietary, protected, and would be nearly impossible to imitate."

Ghalili plans to initially introduce the immune booster to the US market through the network of more than 50 sales representatives who are part of other pending acquisition Five Leaf Labs.

"With this novel patented product, its unique immune boosting capabilities, its enhanced hemp seed oil addition and a strong sales and distribution network, we expect the upcoming launch of our immune booster to generate strong revenue immediately following its mid-July product launch," Ghalili said.

Pressure BioSciences, Cannaworx and SkinScience Labs Inc are set to merge and become Avaiia Bio. The combined business has an intellectual property estate of 31 issued and a dozen or more pending patents, as well as an existing global base of hundreds of corporate and thousands of retail customers.

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

**Price:** 2.5

**Market Cap:** \$9.71 m

### 1 Year Share Price Graph



December 2019 June 2020 December 20

### Share Information

**Code:** PBIO

**Listing:** OTCQB

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.49	0.6006

**Sector:** Medical technology & services

**Website:** [www.pressurebiosciences.com](http://www.pressurebiosciences.com)

### Company Synopsis:

*Pressure BioSciences Inc. (OTCQB: PBIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).